Men's health telehealth has fragmented into a handful of distinct verticals in the UK since 2020 — ED, hair loss, TRT, premature ejaculation, and mental health. Each carries its own regulatory profile, clinical pathway, and conversion economics. This piece is a structural overview for brand operators evaluating where to play.
The categories — ED, hair loss, TRT, PE, mental health
Five categories dominate the men's-health telehealth market in 2026. ED (erectile dysfunction) has the largest patient volume and the highest commodity competition. Hair loss is steady, low-margin, and high-LTV. TRT (testosterone replacement) is highest-margin and highest-regulatory-bar. Premature ejaculation is small but loyal. Men's mental health is growing but underdeveloped commercially.
Regulatory profile of each category
Sildenafil 50mg is now classified as a P (Pharmacy) medicine in the UK, available without prescription with pharmacist consultation. Finasteride 1mg for hair loss remains POM. Testosterone is a Schedule 4 controlled drug requiring careful prescribing and monitoring. Mental-health prescribing carries CD obligations for some medications and Article 9 special-category data implications throughout.
The clinical pathway considerations
ED and hair loss can be assessed asynchronously in low-risk patients with robust red-flag screening. TRT requires synchronous consultation or in-person assessment for initiation; ongoing monitoring (testosterone levels, haematocrit, prostate markers) is required. Mental health requires synchronous assessment by appropriately qualified clinicians.
What conversion looks like across the funnel
ED converts well from broad paid acquisition because the patient demand is concrete. Hair loss converts well from content-led acquisition because the patient journey is longer. TRT requires educated, screened patients — broad acquisition is wasteful. Mental health converts from organic and partnership channels more than paid.
TRT specifically — testosterone is controlled, clinical bar is higher
Testosterone is a Schedule 4 controlled drug. Prescribing requires careful documentation of suitability, exclusion of contraindications, and ongoing monitoring. Compounded testosterone preparations are dispensed under MHRA Specials regulations where licensed alternatives do not meet patient need. ASA scrutinises TRT advertising closely.
Brand positioning — clinical-first vs lifestyle-first messaging
Two positioning approaches dominate. Clinical-first messaging (medical credibility, prescriber-led copy, conservative marketing) builds slower but defensibly. Lifestyle-first messaging (broader appeal, performance/wellness framing) builds faster but attracts more regulator attention. ASA prohibits advertising of POM medicines directly to the UK public, which constrains the lifestyle approach materially.
ASA prohibits advertising of POM medicines directly to the UK public. Prescriber-led copy is the compliant framework — direct product naming in patient-facing ads is not.
Two positioning approaches: clinical-first builds slower but defensibly. Lifestyle-first builds faster but attracts more regulator attention.
Men's health telehealth in 2026 is a real, sustainable category. The brands winning long-term are the ones with clinical-first positioning, robust patient screening, and tight marketing compliance. The brands losing long-term are the ones who treated regulation as a marketing constraint to work around.
